Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position

Avijit Datta,1,2 Rhiannon Smith,2 Francesca Fiorentino,3 Tom Treasure4

ABSTRACT

Background Europe is at the peak of an epidemic of malignant pleural mesothelioma and the burden of disease is likely to continue rising in the large areas of the world where asbestos remains unregulated. Patients with mesothelioma present with thoracic symptoms and radiological changes so respiratory physicians take a leading role in diagnosis and management. Belief that the modest survival times reported after radical surgery, whether alone or as part of multimodal therapy, are longer than they would have been without surgery relies on data from highly selected, uncontrolled, retrospectively analysed case series. The only randomised study, the Mesothelioma and Radical Surgery (MARS) trial showed no benefit. A simple modelling study of registry patients, described here, shows that an impression of longer survival is eroded when patients who were never candidates for operation on grounds of histology, performance status and age are sequentially excluded from the model.

Conclusion Whenever the question arises ‘Might an operation help me?’ there are two responses that can and should be given. The first is that there is doubt about whether there is any survival or symptomatic benefit from surgery but we know that there is harm. The second is that there are on-going studies, including two randomised trials, which patients should be informed about. The authors suggest that the default position for clinicians should be to encourage recruitment into these trials.

Europe is at the peak of an epidemic of malignant pleural mesothelioma and the burden of disease is likely to continue rising in the large areas of the world where asbestos remains unregulated. Respiratory physicians perforce take a lead role in diagnosis and management; patients with mesothelioma present with thoracic symptoms and radiological changes. Whenever the question arises ‘Might an operation help me?’ there are two responses that can and should be given. The first is that we are unsure whether there is any benefit from surgery but that there is harm. The second is that there are ongoing studies, including two randomised trials, which patients should be encouraged to learn more about.

Two forms of extirpative surgery have been performed since the 1970s: extrapleural pneumonectomy (EPP) and lung sparing resection, now commonly referred to as pleurectomy decortication (P/D). They have been the subject of systematic reviews and the searches for each found 58 reports in the form of uncontrolled follow-up studies from which were selected 34 and 26 publications, respectively, for analysis of survival and perioperative data. These retrospective cohort studies are the commonest form of surgical reporting, providing survival data for a single surgeon or an institution’s series of operations, but without control data for direct comparison. The review of EPP opens with a statement that overall survival is less than 12 months, citing a 1989 report of survival among patients diagnosed from 1965 to 1984 and a randomised trial of chemotherapy, which clearly states that the patients studied were not eligible for surgery. Setting the scene with inappropriate survival data, typically from another era, is characteristic of the scene setting introductions to these surgical reports. The implication that longer survival among the cohort of operated patients being reported is attributable to surgery neglects the fact that the operation was not a chance or random occurrence. Surgery is linked to a rigorous and well-informed process of patient selection. A disarmingly simple study illustrates the phenomenon.

Ten patients who had been selected to have EPP from among 123 patients diagnosed with mesothelioma between November 2002 and November 2011 in the Cancer Registry of York Teaching Hospital, an area with a high and still increasing incidence, were identified. For all 123 patients, date of birth, date of diagnosis, histological diagnosis, performance status (PS), alive/dead status and date of death were retrievable from the registry. The Kaplan Meier (KM) survival estimate for the 10 patients who had EPP is shown in each successive graph (figure 1) accompanied by KM survival subsets of the 113 who did not have EPP, derived by stepwise exclusion of patients, recorded in the database, with characteristics that would have precluded them from having EPP.

Step 1: Sarcomatoid histology is an adverse prognostic feature and none of the patients operated on had that pathology, so 11 patients with sarcomatoid histology have to be excluded from comparison.

Step 2: Poor PS (0–4 where 4 is worst) is a clinical reason for exclusion from major surgery within a trimodality package, including both high dose radiotherapy and chemotherapy. Only patients with known PS 0 or 1 were operated on, so a further 29 patients with documented PS 2, 3 or 4 should be excluded from comparison.
Step 3: The oldest patient having EPP was 76.2 years (an unusually advanced age for this surgery), so a further 24 patients older than that age were next excluded from comparison.

It is thus evident that well over half the non-operated patients in York were never candidates for surgery on explicit criteria recorded in the database. Our exclusions are in each case conservative. If other factors available to those making the clinical decision, such as tumour bulk, invasiveness and lymph node involvement, had been balanced between the operated and non-operated patients, the narrowing gap in the survival analysis is likely to have diminished further.

In the Mesothelioma and Radical Surgery (MARS) trial in which patients were randomly allocated to have or to not have EPP the survival difference was in favour of not having surgery (HR 2.75). This was statistically unlikely to have been a chance finding (p=0.016). Note though that MARS was not a shot in the dark. From published data already available in 2004, it was evident that there was unlikely to be a large effect size in favour of EPP. The power calculation for the MARS trial was based on contemporary survival in non-operated patients and a systematic review of EPP at the time and 670 randomised patients were required to be reasonably sure of not missing a survival advantage attributable to EPP hence MARS opened as a feasibility study with the stated intent that the data would contribute to full trial if it went ahead. In the event, after 50 patients had been randomised, benefit from EPP appeared improbable. The admissibility of MARS as evidence (a small trial reporting results from its feasibility phase) has been contested and MARS is an instance of the Lilford maxim ‘some unbiased evidence is clearly better than none’.21

The debate has moved on. EPP cohort studies published in 2007–2009 reported median survival times of 10, 12, 13 and 14 months, while P/D has been associated with similar or better reported outcomes and less impairment of quality of life.27 We cannot be sure from the existing forms of evidence whether it is that P/D is more effective or that it is just less damaging, and hence, it is the subject of two trials.6 The European Organisation for Research and Treatment of Cancer (EORTC) will conduct a randomised trial in which all patients have both P/D and four cycles of neoadjuvant chemotherapy (cisplatin/pemetrexed). It is the sequence (surgery before vs surgery after chemotherapy) that is under test. This study is intended to evaluate which is safer and more feasible.6 It cannot test whether P/D offers benefits compared with no surgery since P/D is in both arms. The MARS-2 trial will address that question. It will investigate survival and patient reported outcomes with extended P/D following chemotherapy versus chemotherapy only.28

It will be some time before we have results from these trials. Meanwhile how can respiratory physicians best advise their patients? The National Collaborative Cancer Network Guidelines for Patients (‘an alliance of 21 of the world’s leading
cancer centers) includes both P/D and EPP in its 2012 Guidelines for Patients. The International Mesothelioma Interest Group (IMIG) advise that surgical cytoreduction is indicated when macroscopic complete resection is deemed achievable and that the type of surgery (EPP or P/D) depends on clinical factors and on individual surgical judgment and expertise. The IMIG statement is under the heading ‘Clinical Guidelines’ but is in reality a position statement from the most eminent and experienced surgeons working with this cancer. Ten of the twelve IMIG authors are surgeons and 7 of their 10 citations are to IMIG conference abstracts, which feature uncontrolled follow-up studies of highly selected patients. The IMIG statement contrasts with recommendations from the Guidelines for Patients. 29 The International Mesothelioma Database (IMD) guidelines state that the preferred treatment for patients with malignant pleural mesothelioma is EPP. Excluding histology, 102 of 113 patients with malignant pleural mesothelioma had non-curative-intent surgery. 30 This appears to be implicitly accepted in the phrase ‘consideration of surgery if the more extensive EPP consistently fails to do so’. This is strange, considering that to date there is no report of a single patient surviving (malignant pleural mesothelioma). The problem is that the sense of the action ‘to cure’ is not clear to all or it is differently thought about in the thoracic surgeons community. 

Does surgery provide net benefit with respect to pain, respiratory symptoms, quality of life and other patient reported outcomes? This information cannot be retrieved from the existing systematic reviews. 7 A recent prospective study reported a substantial impairment of quality of life following surgery, worse for EPP than P/D, and only after P/D did quality of life return to baseline, and that took 12 months. 27 Similar findings for respiratory function have now been reported. 36 There appears to be a place for an approach in which treatment is moderated and in which the primary outcome shifts from survival to giving the patient the best remaining months or years. 37 If patients are to be considered for surgery, given the lack of good quality evidence, recruitment into one or other of the two trials should be considered as the default position by respiratory physicians, surgeons and oncologists. 38

Table 1 Stepwise exclusion of patients, recorded in the database, with characteristics which would have precluded EPP

<table>
<thead>
<tr>
<th>N</th>
<th>Median survival (Months)</th>
<th>IQR survival (Months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Non-EPP</td>
<td>113</td>
<td>6.1</td>
</tr>
<tr>
<td>Excluding Sarcomatoid histology</td>
<td>102</td>
<td>6.15</td>
</tr>
<tr>
<td>Then excluding PS 2, 3 or 4*</td>
<td>73</td>
<td>9.6</td>
</tr>
<tr>
<td>Then excluding age &gt;76.2 years</td>
<td>49</td>
<td>11.4</td>
</tr>
<tr>
<td>Patients who had EPP</td>
<td>10</td>
<td>12.6</td>
</tr>
</tbody>
</table>

*Patients with PS missing are included. EPP, extrapleural pneumonectomy; PS, performance status.

REFERENCES